drugset / Trial / NCT06500507
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose.
Timeline
- Start
- 2024-08-30
- Primary completion
- 2026-03-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLS4131 | Monoclonal antibody | 0.06 ug/kg | — |
| Subject | QLS4131 | Monoclonal antibody | 0.3 ug/kg | — |
| Subject | QLS4131 | Monoclonal antibody | 1 ug/kg | — |
| Subject | QLS4131 | Monoclonal antibody | 600 ug/kg | — |